Logo

LAVA Therapeutics N.V.

LVTX

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAV… read more

Healthcare

Biotechnology

2 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$1.57

Price

+0.66%

$0.01

Market Cap

$41.307m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$4.990m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$28.383m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$1.05

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$19.935m

$60.547m

Assets

$40.612m

Liabilities

-

Debt
Debt to Assets

0.00%

-

Debt to EBITDA
Free Cash Flow

-$21.782m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases